Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Phase 2 Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (GIANT)

NCT06816927 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT06816927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06816927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Phase 2 Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (GIANT)
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Recruiting
Start date
November 28, 2025
Completion date
June 1, 2031
Enrollment
92 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed glioblastoma